These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16740585)

  • 61. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Human papillomavirus vaccination. Consensus Conference in pediatric age].
    Bartolozzi G; Bona G; Ciofi M; De Martino M; Di Pietro P; Duse M; Esposito S; Gasparini R; Mariani L; Marostica G; Paravati F; Plebani A; Principi N; Zuccotti GV; Tovo PA
    Minerva Pediatr; 2007 Jun; 59(3):165-82. PubMed ID: 17519861
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.
    Khan K; Curtis CR; Ekwueme DU; Stokley S; Walker C; Roland K; Benard V; Saraiya M
    Cancer; 2008 Nov; 113(10 Suppl):3004-12. PubMed ID: 18980296
    [TBL] [Abstract][Full Text] [Related]  

  • 66. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
    Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of human papillomavirus vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Markowitz LE
    Emerg Infect Dis; 2008 Feb; 14(2):244-51. PubMed ID: 18258117
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HPV vaccine and males: issues and challenges.
    Zimet GD; Rosenthal SL
    Gynecol Oncol; 2010 May; 117(2 Suppl):S26-31. PubMed ID: 20129653
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?
    Marsh K; Chapman R; Baggaley RF; Largeron N; Bresse X
    Vaccine; 2014 Jun; 32(30):3732-9. PubMed ID: 24837538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vaccination against multiple HPV types.
    Elbasha EH; Galvani AP
    Math Biosci; 2005 Sep; 197(1):88-117. PubMed ID: 16095627
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.
    Vanagas G; Padaiga Z
    Scand J Public Health; 2012 Jul; 40(5):406-11. PubMed ID: 22821227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.
    Westra TA; Rozenbaum MH; Rogoza RM; Nijman HW; Daemen T; Postma MJ; Wilschut JC
    J Infect Dis; 2011 Aug; 204(3):377-84. PubMed ID: 21742836
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.
    Zechmeister I; Blasio BF; Garnett G; Neilson AR; Siebert U
    Vaccine; 2009 Aug; 27(37):5133-41. PubMed ID: 19567244
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine.
    Kane MA
    Gynecol Oncol; 2010 May; 117(2 Suppl):S32-5. PubMed ID: 20129654
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
    Murillo R; Ordóñez-Reyes C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human papilloma vaccination to adolescents.
    Levavi H
    Pediatr Endocrinol Rev; 2010 Sep; 8(1):2-5. PubMed ID: 21037538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.